Trial
NCT03196401
A Study of Durvalumab (Anti-PDL1) Plus Radiation Therapy for the Treatment of Solitary Bone Plasmacytoma
Phase IWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Memorial Sloan Kettering Cancer Center
Collaborators
Celgene Corporation
Condition
Solitary Bone Plasmacytoma
Intervention
Durvalumab
Why stopped
FDA recommendation
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-08-03